Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis.
about
Sumoylation of critical proteins in amyotrophic lateral sclerosis: emerging pathways of pathogenesisNeuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative diseaseNovel molecular biomarkers at the blood-brain barrier in ALSHigh-affinity glutamate transporters in chronic pain: an emerging therapeutic targetImplication of Genetic Deletion of Wdr13 in Mice: Mild Anxiety, Better Performance in Spatial Memory Task, with Upregulation of Multiple Synaptic Proteins.Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophyIL-12p40 deficiency leads to uncontrolled Trypanosoma cruzi dissemination in the spinal cord resulting in neuronal death and motor dysfunctionRole of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute NeuropathologiesCaveolin-1 Sensitivity of Excitatory Amino Acid Transporters EAAT1, EAAT2, EAAT3, and EAAT4.Acute death of astrocytes in blast-exposed rat organotypic hippocampal slice culturesDrosophila TDP-43 dysfunction in glia and muscle cells cause cytological and behavioural phenotypes that characterize ALS and FTLDAdeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model.p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.Sumoylation of the astroglial glutamate transporter EAAT2 governs its intracellular compartmentalizationPathological correlations between traumatic brain injury and chronic neurodegenerative diseases.Self-induced accumulation of glutamate in striatal astrocytes and basal ganglia excitotoxicity.Persistent inward currents in spinal motoneurons: important for normal function but potentially harmful after spinal cord injury and in amyotrophic lateral sclerosis.Changes in the astrocytic aquaporin-4 and inwardly rectifying potassium channel expression in the brain of the amyotrophic lateral sclerosis SOD1(G93A) rat model.Unlike physical exercise, modified environment increases the lifespan of SOD1G93A mice however both conditions induce cellular changes.Astroglial inhibition of NF-κB does not ameliorate disease onset and progression in a mouse model for amyotrophic lateral sclerosis (ALS)Exposure of neurons to excitotoxic levels of glutamate induces cleavage of the RNA editing enzyme, adenosine deaminase acting on RNA 2, and loss of GLUR2 editing.Case-control study of ADARB1 and ADARB2 gene variants in migraine.Dietary Vitamin D3 Restriction Exacerbates Disease Pathophysiology in the Spinal Cord of the G93A Mouse Model of Amyotrophic Lateral SclerosisRefinement of the Central Steps of Substrate Transport by the Aspartate Transporter GltPh: Elucidating the Role of the Na2 Sodium Binding SiteAn over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1GLT-1-Dependent Disruption of CNS Glutamate Homeostasis and Neuronal Function by the Protozoan Parasite Toxoplasma gondii.Transgenic GDNF Positively Influences Proliferation, Differentiation, Maturation and Survival of Motor Neurons Produced from Mouse Embryonic Stem Cells.Gacyclidine improves the survival and reduces motor deficits in a mouse model of amyotrophic lateral sclerosis.Motor neuron impairment mediated by a sumoylated fragment of the glial glutamate transporter EAAT2Analysis of the hippocampal proteome in ME7 prion disease reveals a predominant astrocytic signature and highlights the brain-restricted production of clusterin in chronic neurodegeneration.State of the art and the dark side of amyotrophic lateral sclerosis.Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis.Vitamin D as a potential therapy in amyotrophic lateral sclerosis.Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.Non-neuronal Cells in ALS: Role of Glial, Immune cells and Blood-CNS Barriers.Transporters as Drug Targets in Neurological DiseasesCopy Number Variations in Amyotrophic Lateral Sclerosis: Piecing the Mosaic Tiles Together through a Systems Biology Approach.Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis.Altered astrocytic response to activation in SOD1(G93A) mice and its implications on amyotrophic lateral sclerosis pathogenesis.
P2860
Q26866679-F349A120-BC58-4134-92D7-E14013763701Q26995351-78448BA3-E95F-4B65-9B62-F12A6801C669Q27004431-477AF272-3F21-44AB-82AE-D0F78966E88EQ27020953-70A389C9-713E-4EAF-B63E-A126D014E153Q27308729-E0A0B8ED-DED6-4CA3-B251-2CB6EDE0D704Q27312456-BE0B81C7-A487-4DB4-B824-BB5DA177D7C4Q27339616-27AAF8C9-1843-4ADB-A95E-87E948AB151AQ28072353-292753D5-8A3A-47DC-9B1F-B7454030D2B1Q30090165-7713F8CD-F5D2-43B9-8BBF-2AAF287F36BFQ30361334-CE039D2E-FB40-4B5C-8F30-8F789BD9FB55Q30544252-0D8C37BE-CA80-4A9F-847A-D25CD0405600Q30843477-58DCFBB9-2484-4022-A42D-AB6ED6D3D843Q33556826-4B96AF49-A556-4F6A-AD77-5C01DB1389F8Q33769417-A20DF399-E6AE-47D5-A7A5-4EC5200AFC25Q33891870-4ADE72BC-35C6-4595-B3A9-C7D66CB584F8Q34310129-8880036D-9356-4AD6-B04C-413062F6F37CQ34399203-D1CE9342-9389-443F-AC4E-C7122F2418DCQ34417341-C409D717-C694-4A35-A4A3-8A76E3E0E403Q34429228-58A0C10A-5115-4A8E-89D0-8C435CBB4F73Q34698706-145032E0-D1A4-4AC1-B901-174A7318B3B9Q35147567-8C1FFADA-E6AC-4FAC-89DC-743BA4CBCD65Q35418914-EF7D8F8F-3171-4DA1-8F5D-423297EFFD6BQ35645195-2CD6ED90-5E8B-4713-A835-FCDB7430E3DBQ35814637-38595FD7-124C-45CC-B30C-5475CE9C3909Q35882558-EE0D2E53-F4DD-4A41-B699-7F76311D8A8FQ36047101-A48E3A4F-A9AB-4DA9-9E15-1E567FFAF85FQ37246814-96284EB4-E41B-4374-9BB6-A7F2FA385015Q37415516-732D548F-2CC0-4A98-935E-C5D31540F20CQ37495585-CA2DC4C5-334D-4361-A43B-946005812DBAQ37583628-958C31C1-3A84-4063-8434-2BF3A1C65E91Q37871837-7D6B743E-45D4-4388-B41C-985ACA57764AQ37952528-1253E753-833B-4C24-B6C3-D28250A4A69CQ38178758-234B43EF-76FA-47F2-B0AB-29C8058AA020Q38395012-20CD7829-19A5-4A72-8926-46A157A64273Q38563981-091AF29C-CC71-44C5-AFA7-0BC7C8207072Q38701186-1D63CB58-93BB-49F0-A09E-9249962F0E56Q38905608-D3FA413D-E31F-4A18-A6A7-CD90CCC3A53CQ39102149-33CE5853-077A-4105-9303-B4DBDAF53AB5Q39215660-6A91660C-8DF9-418E-8FB5-3A5BE3237598Q39217922-8955186D-BCD6-4F82-8ACA-CFA70A0609D0
P2860
Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Glutamate transporters and the ...... amyotrophic lateral sclerosis.
@ast
Glutamate transporters and the ...... amyotrophic lateral sclerosis.
@en
type
label
Glutamate transporters and the ...... amyotrophic lateral sclerosis.
@ast
Glutamate transporters and the ...... amyotrophic lateral sclerosis.
@en
prefLabel
Glutamate transporters and the ...... amyotrophic lateral sclerosis.
@ast
Glutamate transporters and the ...... amyotrophic lateral sclerosis.
@en
P2860
P356
P1476
Glutamate transporters and the ...... amyotrophic lateral sclerosis.
@en
P2093
Davide Trotti
Emily Foran
P2860
P304
P356
10.1089/ARS.2009.2444
P577
2009-07-01T00:00:00Z